VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma

Sutapa Sinha, Ying Cao, Shamit Dutta, Enfeng Wang, Debabrata Mukhopadhyay

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies and affects approximately three in 10,000 people. The impact of this disease produces about 31,000 new cases in the United States per year; and 12,000 people in the United States alone die from RCC annually. Although several treatment strategies have been investigated for RCC, this cancer continues to be a therapeutic challenge. For this reason, the aim of our study is to develop a more effective combinational therapy to treat advanced RCC. We examined the effect of vinorelbine on the signalling pathways of two human renal cancer cell lines (A498 and 786-O) and also examined the in vivo effect of vinorelbine treatment alone and vinorelbine in combination with the anti-VEGF antibody 2C3 on A498 and 786-O tumour growth in nude mice. Tumour angiogenesis was measured by vWF staining, and apoptosis was determined by the TUNEL assay. We observed a significant tumour growth inhibition when using a combinational therapy of anti-VEGF antibody 2C3 and vinorelbine in both A498 and 786-O tumour-bearing mice. The results suggest a breakthrough treatment for advanced RCC.

Original languageEnglish (US)
Pages (from-to)647-658
Number of pages12
JournalJournal of Cellular and Molecular Medicine
Volume14
Issue number3
DOIs
StatePublished - Mar 2010

Fingerprint

Neutralizing Antibodies
Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Neoplasms
Anti-Idiotypic Antibodies
Therapeutics
Kidney Neoplasms
In Situ Nick-End Labeling
Growth
Nude Mice
vinorelbine
Apoptosis
Staining and Labeling
Cell Line

Keywords

  • Mice model
  • Renal cell carcinoma
  • Vinorelbine and 2C3

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Medicine

Cite this

VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma. / Sinha, Sutapa; Cao, Ying; Dutta, Shamit; Wang, Enfeng; Mukhopadhyay, Debabrata.

In: Journal of Cellular and Molecular Medicine, Vol. 14, No. 3, 03.2010, p. 647-658.

Research output: Contribution to journalArticle

@article{2af0cd83664d4d28bc8019ee0047cf0c,
title = "VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies and affects approximately three in 10,000 people. The impact of this disease produces about 31,000 new cases in the United States per year; and 12,000 people in the United States alone die from RCC annually. Although several treatment strategies have been investigated for RCC, this cancer continues to be a therapeutic challenge. For this reason, the aim of our study is to develop a more effective combinational therapy to treat advanced RCC. We examined the effect of vinorelbine on the signalling pathways of two human renal cancer cell lines (A498 and 786-O) and also examined the in vivo effect of vinorelbine treatment alone and vinorelbine in combination with the anti-VEGF antibody 2C3 on A498 and 786-O tumour growth in nude mice. Tumour angiogenesis was measured by vWF staining, and apoptosis was determined by the TUNEL assay. We observed a significant tumour growth inhibition when using a combinational therapy of anti-VEGF antibody 2C3 and vinorelbine in both A498 and 786-O tumour-bearing mice. The results suggest a breakthrough treatment for advanced RCC.",
keywords = "Mice model, Renal cell carcinoma, Vinorelbine and 2C3",
author = "Sutapa Sinha and Ying Cao and Shamit Dutta and Enfeng Wang and Debabrata Mukhopadhyay",
year = "2010",
month = "3",
doi = "10.1111/j.1582-4934.2008.00578.x",
language = "English (US)",
volume = "14",
pages = "647--658",
journal = "Journal of Cellular and Molecular Medicine",
issn = "1582-1838",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - VEGF neutralizing antibody increases the therapeutic efficacy of vinorelbine for renal cell carcinoma

AU - Sinha, Sutapa

AU - Cao, Ying

AU - Dutta, Shamit

AU - Wang, Enfeng

AU - Mukhopadhyay, Debabrata

PY - 2010/3

Y1 - 2010/3

N2 - Renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies and affects approximately three in 10,000 people. The impact of this disease produces about 31,000 new cases in the United States per year; and 12,000 people in the United States alone die from RCC annually. Although several treatment strategies have been investigated for RCC, this cancer continues to be a therapeutic challenge. For this reason, the aim of our study is to develop a more effective combinational therapy to treat advanced RCC. We examined the effect of vinorelbine on the signalling pathways of two human renal cancer cell lines (A498 and 786-O) and also examined the in vivo effect of vinorelbine treatment alone and vinorelbine in combination with the anti-VEGF antibody 2C3 on A498 and 786-O tumour growth in nude mice. Tumour angiogenesis was measured by vWF staining, and apoptosis was determined by the TUNEL assay. We observed a significant tumour growth inhibition when using a combinational therapy of anti-VEGF antibody 2C3 and vinorelbine in both A498 and 786-O tumour-bearing mice. The results suggest a breakthrough treatment for advanced RCC.

AB - Renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies and affects approximately three in 10,000 people. The impact of this disease produces about 31,000 new cases in the United States per year; and 12,000 people in the United States alone die from RCC annually. Although several treatment strategies have been investigated for RCC, this cancer continues to be a therapeutic challenge. For this reason, the aim of our study is to develop a more effective combinational therapy to treat advanced RCC. We examined the effect of vinorelbine on the signalling pathways of two human renal cancer cell lines (A498 and 786-O) and also examined the in vivo effect of vinorelbine treatment alone and vinorelbine in combination with the anti-VEGF antibody 2C3 on A498 and 786-O tumour growth in nude mice. Tumour angiogenesis was measured by vWF staining, and apoptosis was determined by the TUNEL assay. We observed a significant tumour growth inhibition when using a combinational therapy of anti-VEGF antibody 2C3 and vinorelbine in both A498 and 786-O tumour-bearing mice. The results suggest a breakthrough treatment for advanced RCC.

KW - Mice model

KW - Renal cell carcinoma

KW - Vinorelbine and 2C3

UR - http://www.scopus.com/inward/record.url?scp=77953490722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953490722&partnerID=8YFLogxK

U2 - 10.1111/j.1582-4934.2008.00578.x

DO - 10.1111/j.1582-4934.2008.00578.x

M3 - Article

C2 - 19017359

AN - SCOPUS:77953490722

VL - 14

SP - 647

EP - 658

JO - Journal of Cellular and Molecular Medicine

JF - Journal of Cellular and Molecular Medicine

SN - 1582-1838

IS - 3

ER -